Myostatin inhibitors

Myostatin inhibitors improve muscle function.

“demonstrated encouraging results in preclinical and early clinical studies by increasing muscle mass and improving muscle function.”

Reviewin preclinical and early clinical studies

Myostatin inhibitors in sarcopenia treatment: A comprehensive review of mechanisms, efficacy and future directions

Molecular biology reports·29 Dec 2025

Myostatin inhibitors increase muscle mass.

“Myostatin inhibitors-comprising direct agents such as monoclonal antibodies and small molecules, as well as indirect modulators including follistatin-based strategies and other pathway regulators-have demonstrated encouraging results in preclinical and early clinical studies by increasing muscle mass”

Reviewin preclinical and early clinical studies

Myostatin inhibitors in sarcopenia treatment: A comprehensive review of mechanisms, efficacy and future directions

Molecular biology reports·29 Dec 2025

Myostatin inhibitors increase appendicular lean mass in humans.

“late-phase trials of myostatin-neutralising antibodies (e.g., LY2495655, bimagrumab) and oral selective androgen-receptor modulators (SARMs; e.g., enobosarm, GSK2881078) now show dose-dependent gains in appendicular lean mass”

Reviewsarcopenia

Sarcopenia in Aging: Pathogenesis, Diagnosis, and Emerging Therapeutic Frontiers

Molecular imaging and biology·26 Nov 2025